Cumulative risk of CNS disease in “high-risk” patients. (A) All patients with elevated lactate dehydrogenase (LDH), involvement of > 1 extranodal site, and presence of B-symptoms versus all other patients. (B) Patients treated with R-CHOP–14 and elevated LDH, involvement of > 1 extranodal site, and Eastern Cooperative Oncology Group performance status > 1 versus all other patients treated with R-CHOP–14.